MRKR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Marker Therapeutics Inc (MRKR) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, and the financial performance is weak with declining revenue, net income, and EPS. Additionally, there are no significant positive catalysts or trading signals to support an immediate investment.
The MACD is negative and expanding, indicating a bearish trend. RSI is at 29.65, which is neutral but close to oversold territory. The stock is trading below key pivot levels with support at 1.403 and resistance at 1.619, suggesting limited upside potential in the short term.
H.C. Wainwright initiated coverage with a Buy rating and a $10 price target, citing the company's innovative MAR-T cell therapies and leadership potential in cancer immunotherapy.
Weak financial performance in Q3 2025 with significant declines in revenue (-35.99% YoY), net income (-13.41% YoY), and EPS (-53.85% YoY). Technical indicators suggest a bearish trend, and there is a high probability of further short-term price declines.
In Q3 2025, revenue dropped by 35.99% YoY, net income declined by 13.41% YoY, and EPS fell by 53.85% YoY. Gross margin remained stable at 100%, but the overall financial performance is weak.
H.C. Wainwright analyst Patrick Trucchio initiated coverage with a Buy rating and a $10 price target, highlighting the company's innovative pipeline and leadership potential in cancer immunotherapy.
